Detalhe da pesquisa
1.
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Lancet
; 399(10320): 161-171, 2022 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861168